Gambogic acid decreases BCR-ABL by activating the caspase system both in imatinib resistant and sensitive CML cells [14], while platinum pyrithione downregulates BCR-ABL through inhibiting BCR-ABL transcription, as well as degrading BCR-ABL caspase dependently [15]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.